Parexel, a global clinical development partner providing insights-driven clinical and consulting solutions, has acquired Vitrana, a provider of AI-enabled, end-to-end pharmacovigilance (PV) technology platforms, for an undisclosed sum.
The acquisition provides Parexel an integrated PV platform that leverages intelligent automation and AI to accelerate end-to-end Patient Safety & PV processes, deliver first-time quality and enhance compliance.
The technology platform is system-agnostic and integrates with any safety database – allowing customers to deploy the capabilities that best fit their needs – improving accuracy, cycle times and delivering measurable and sustainable efficiencies.
“With Vitrana, we can now offer customers a single partner for both PV technology and services – and that changes what we can deliver for them. Our customers will benefit from best-in-class, technology-enabled PV services that handle growing regulatory volume and complexity, enhance compliance, streamline workflows, and enable experts to focus on what matters most: product and patient safety,” Sanjay Vyas, President of Patient Safety Services & Clinical Logistics, and Managing Director of India, Parexel.
“We’re thrilled to join Parexel and further scale our proven technology and our experienced team as we strengthen pharmacovigilance solutions,” said Mohit Gupta, President and CEO, Vitrana. “Together, we can offer improved efficiency, quality and compliance to our customers worldwide.”
Noida-based Vitrana’s team of 600 employees and technology would be aligned with Parexel’s Patient Safety Services organisation, providing a seamless transition and continuity of services to customers, the release added.